Verbatim response from Perplexity
Several telehealth services still appear to offer compounded GLP-1s, but the landscape changed sharply after the FDA’s March 2026 warning letters, and some companies have already shifted to branded products or stopped compounded offerings altogether.[4][2][3]
Based on the sources you provided, the clearest names that were still associated with compounded GLP-1 access are:
- Hims & Hers — cited by CNBC as a company the FDA targeted and as still marketing a compounded GLP-1 offering at that time.[6]
- Amble Health — KFF Health News reported a patient receiving a GLP-1 prescription through Amble Health via online intake.[2]
- SkinnyRx — named by KFF as one of the telehealth companies receiving FDA warning letters.[2]
- Join Josie — named by KFF as another warned telehealth company.[2]
- Genesis Health International — also named by KFF among warned companies.[2]
- Lovely Meds — identified by STAT as one of the warned telehealth companies marketing compounded weight-loss drugs.[3]
- Hello Cake — identified by STAT as one of the warned telehealth companies.[3]
- MEDVi — identified by STAT as one of the warned telehealth companies.[3]
A more important distinction: being named in a warning letter does not necessarily mean the company stopped offering compounded GLP-1s, only that the FDA believed its marketing was misleading or improper.[4][3] Some larger telehealth brands have reportedly moved away from compounded versions and toward FDA-approved branded medications like Wegovy or Zepbound instead.[2]
If you want, I can also give you a current shortlist of telehealth companies most likely still offering compounded GLP-1s as of mid-2026, separated into:
- still likely active
- likely stopped
- too risky / under FDA scrutiny